LIPITOR Drug Patent Profile

When do Lipitor patents expire, and what generic alternatives are available?

Lipitor is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lipitor

A generic version of LIPITOR was approved as atorvastatin calcium by APOTEX INC on May 29^th, 2012.

Summary for LIPITOR

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIPITOR

US Patents and Regulatory Information for LIPITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	AB	RX	Yes	No
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	AB	RX	Yes	Yes
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	AB	RX	Yes	No
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	AB	RX	Yes	No

International Patents for LIPITOR

See the table below for patents covering LIPITOR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	60602
Australia	601981
Australia	7315987
Canada	1268768	INHIBITEURS DE LA SYNTHESE DU CHOLESTEROL DE TYPE TRANS-6-[2-(2 OU 4-CARBOXAMIDO(SUBSTITUE)PYRROL-1- YL)ALKYL]-4-HYDROXYPYRAN-2-ONE (TRANS-6-[2-(3- OR 4-CARBOXAMIDO-SUBSTITUTED PYRROL- 1-YL)ALKYL]-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS)
Germany	19775019
Germany	3767770
Denmark	171588

Supplementary Protection Certificates for LIPITOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0720599	CR 2014 00050	Denmark		PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
1003503	05C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0247633	97C0103	Belgium		PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
1003503	SZ 30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
1003503	30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707

LIPITOR (atorvastatin) Investment Scenario & Fundamentals Analysis

Last updated: April 24, 2026

What is LIPITOR’s commercial profile today?

LIPITOR (atorvastatin) is a first-in-class, widely used HMG-CoA reductase inhibitor (statin) and one of the largest branded oral therapies globally by historical sales. Commercial fundamentals are now driven by two forces: (1) permanent replacement by generics across major markets and (2) brand-residual economics from price management, contract formularies, and patient switching friction.

Core business reality: LIPITOR remains a legacy cash-flow asset in many portfolios because generic entry does not uniformly erase branded volumes. Contracting and switching costs sustain some branded share in certain channels, even after expiry-driven generic erosion.

---

What do the key fundamentals indicate for long-term earnings?

1) Market structure: brand erosion after generic entry

The investment case for LIPITOR now relies on the gap between branded and generic behavior:

• Generic penetration: High, with steady volume capture after patent expiry.
• Branded resilience: Usually limited to higher-acuity prescriber segments, grandfathered formularies, and brand-specific payer tiers.
• Price compression: Branded price declines toward generic parity over time through rebates and contracting.

2) Evidence of scale: historical blockbuster status

LIPITOR is widely documented as one of the highest-selling drugs in history, with peak annual global sales reaching into the multi-billion-dollar range prior to generic competition. Public disclosures and major industry reporting consistently describe LIPITOR as the defining statin franchise of its era. (See sources below.)

3) Risk factors for branded cash flows

The fundamentals for an on-going branded investment thesis hinge on the following risk map:

• Patent and exclusivity expiry effects: Hard stop on exclusivity for branded supply economics.
• Generic competition: Continued erosion via incremental generic entrants, price undercutting, and pharmacy-level switching.
• Payer formulary tactics: Restrictive tier placement, prior authorization, step therapy, and higher copay differentials.
• Statin category dynamics: Ongoing preference shifts within statins based on comparative efficacy and tolerability perceptions.

---

What are the key drivers of demand in the statin market?

1) Indication coverage

Atorvastatin is used across common lipid and cardiovascular risk management regimens, including:

• Hyperlipidemia and mixed dyslipidemia
• Prevention of cardiovascular events in appropriate patient populations
• Adjunct to diet in lipid control contexts

This breadth supports “category demand” even when the branded asset loses market share.

2) Patient lifetime value dynamics

Once a patient is on long-term lipid therapy, persistence rates can be meaningful, which slows switching. This matters because branded residual share can persist longer than naïve market-share models predict, especially when therapy is stable and adverse-event rates are manageable.

3) Competitive positioning inside statins

Within the class, prescriber selection often balances:

• LDL reduction targets
• Tolerability and muscle-related adverse event history
• Dose adjustment practices
• Patient-specific access (payer coverage and cost-sharing)

Atorvastatin’s broad dosing range and clinical familiarity maintain it as a default option even with generics.

---

How does patent expiry shape investor expectations?

Exclusivity timeline effects

For LIPITOR, the investment framing must assume a post-exclusive branded environment in which profitability depends on contracting, rebate leverage, and the remaining branded channel.

A major expectation follows:

• Branded revenue growth becomes replacement-by-contract rather than prescription net growth.
• Upside is limited to share retention and pricing discipline rather than “market creation.”

---

What does the risk-adjusted outlook look like?

1) Generic pricing pressure

Generic atorvastatin prices generally trend downward. This affects any branded revenue remaining through:

• Payer reimbursement caps
• “Lowest available cost” policies
• Shrinking branded-to-generic price spread

2) Regulatory and labeling drift

Late-life risk comes from:

• Safety labeling updates and class-wide warnings
• Guideline changes affecting intensity of statin use
• Comparative outcomes evidence that can shift preference among statins

In this environment, LIPITOR’s investment thesis is not about scientific superiority. It is about sustained share in a mature market.

3) Execution risks for manufacturers

Branded economics depend on:

• Rebate strategy and formulary positioning
• Supply continuity and cost management
• Marketing spend efficiency in a declining ROI environment

---

Investment scenario: three plausible paths for LIPITOR economics

Base case: steady branded residual cash flow

• Branded volume continues to decline but at a slower rate due to contracting friction and patient persistence.
• Pricing compresses toward generics.
• Operating profitability is maintained through cost controls and mix.

What you’d underwrite: continued stable contribution margin, declining volume trend, and no major payer policy shocks.

Bear case: accelerated erosion

• Payers tighten step therapy and move more tiers to generics.
• Switching increases due to pharmacy programs and cost-sharing changes.
• Branded residual share shrinks faster than expected.

What you’d underwrite: sharper volume declines, lower net price from deeper rebates, and higher promotional costs for remaining share.

Bull case: hold share via contract leverage

• Branded retains disproportionate share in specific high-volume accounts.
• Rebate and formulary negotiation reduces net price decline velocity.
• Generic access is uneven across geographies and channels, keeping branded economics superior.

What you’d underwrite: slower than expected net price erosion and stable branded prescription share.

---

Key metric framework for diligence (what matters in the numbers)

For an investment-grade view, track these metrics at minimum:

Metric	Why it matters now	What a “good” trend looks like
Net sales trend (branded)	Captures price and volume after rebates	Decline slows vs prior periods
Net price vs generic index	Shows contracting and payer pressure	Price compression decelerates
Prescription share retention	Proxy for switching friction	Share decline is gradual
Gross-to-net change	Rebate intensity and list price policies	Stability in gross-to-net ratio
Market growth in statins category	Offsets some share loss	Category growth cushions erosion
Formulary tiering outcomes	Determines patient access	Branded maintains at least partial access

---

Industry context: LIPITOR’s place in global pharma economics

Statins remain foundational

Statins remain a persistent demand class because lipid management and cardiovascular risk reduction are ongoing therapy domains. This keeps category volume alive even when branded share collapses.

Legacy brand economics shift from growth to cash generation

For mature legacy brands, the investment profile changes from “expansion” to “harvest”:

• Lower R&D intensity
• Focus on cost discipline
• Channel and contracting strategy

That structure is consistent with how major branded franchises evolve after exclusivity.

---

Bottom-line investment conclusion

LIPITOR’s investment scenario is a mature cash-flow model with limited upside convexity. The thesis is viable only if branded residual share and net pricing remain sufficiently resilient against generic pricing and payer tier restrictions. Upside comes from share retention and contract leverage, not from new clinical differentiation.

---

Key Takeaways

• LIPITOR is in a post-exclusivity environment where generic competition drives the direction of branded economics.
• The investment case depends on branded residual share, rebate-driven net price, and payer contracting friction.
• Long-term outcomes are best modeled as cash harvest with declining volume, with upside limited to slower erosion and downside accelerated switching.
• Diligence should focus on net sales, gross-to-net, prescription share retention, and formulary tier outcomes.

---

FAQs

1) Is LIPITOR still considered a blockbuster at current market scale?

Historically it is, but today its branded economics operate in a mature, post-generic environment. The market profile is more about residual cash flow than growth.

2) What drives branded LIPITOR performance when generics are widely available?

Formulary placement, rebate dynamics, patient persistence, and switching friction are the main drivers.

3) How should investors think about statin category growth versus brand share loss?

Category demand can cushion declines, but branded performance will track share and net pricing under payer contracting.

4) What is the biggest single risk to a LIPITOR-focused thesis?

Accelerated generic switching and tighter payer policies that reduce branded access and deepen net price compression.

5) What diligence signals best predict whether branded erosion is slowing or accelerating?

Net price versus generic benchmarks, gross-to-net stability, and prescription share retention across major channels.

---

References (APA)

1. Pfizer Inc. (n.d.). LIPITOR (atorvastatin calcium) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drug Databases and Labels (Atorvastatin calcium/ LIPITOR). https://www.fda.gov
3. Bloomberg. (n.d.). Pharmaceutical industry coverage on LIPITOR sales history and generic competition.